2.3.1.129: acyl-[acyl-carrier-protein]-UDP-N-acetylglucosamine O-acyltransferase
This is an abbreviated version!
For detailed information about acyl-[acyl-carrier-protein]-UDP-N-acetylglucosamine O-acyltransferase, go to the full flat file.
Word Map on EC 2.3.1.129
-
2.3.1.129
-
udp-glcnac
-
lipopolysaccharide
-
left-handed
-
acyl-acp
-
endotoxin
-
drug development
-
beta-helix
-
beta-helical
-
homotrimer
-
udp-3-o-r-3-hydroxymyristoyl-glcnac
-
raetz
-
medicine
- 2.3.1.129
- udp-glcnac
- lipopolysaccharide
-
left-handed
- acyl-acp
- endotoxin
- drug development
-
beta-helix
-
beta-helical
-
homotrimer
-
udp-3-o-r-3-hydroxymyristoyl-glcnac
-
raetz
- medicine
Reaction
Synonyms
acyltransferase, uridine diphosphoacetylglucosamine, LiLpxA, LpxA, type II ACP-dependent UDP-N-acetylglucosamine acyltransferase, type II acyl carrier protein-dependent UDP-N-acetylglucosamine acyltransferase, UDP-N-acetylglucosamine 3-O-acyltransferase, UDP-N-acetylglucosamine acyltransferase, uridine diphosphoacetylglucosamine acyltransferase
ECTree
Advanced search results
Application
Application on EC 2.3.1.129 - acyl-[acyl-carrier-protein]-UDP-N-acetylglucosamine O-acyltransferase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
drug development
medicine
structures helps to design new inhibitors that target LpxA, antibiotics
the enzyme is a target for design of inhibitors with antibiotic potency
drug development
-
development of small molecule, dual-binding LpxA/LpxD inhibitors as novel antimicrobials
drug development
-
LpxA is a potential target for antibacterial drug discovery
drug development
-
Lpxa is a viable target for antimicrobial drug development